Loading...
•
Dec 31, 2022
Lyra Q4 2022 Earnings Report
Lyra Therapeutics reported financial results for Q4 2022 and provided a corporate update.
Key Takeaways
Lyra Therapeutics reported a net loss of $14.2 million for the fourth quarter of 2022. The company's cash, cash equivalents, and short-term investments were $97.9 million as of December 31, 2022, and are expected to fund operations into mid-2024. The company transitioned manufacturing to in-house in Q4 2022.
Initiated two pivotal Phase 3 clinical trials of LYR-210 in Chronic Rhinosinusitis (CRS) in Surgically Naïve Patients (ENLIGHTEN I and ENLIGHTEN II).
Initiated BEACON Phase 2 trial of LYR-220 in CRS patients who remain symptomatic despite having had prior sinus surgery.
Transitioned manufacturing to in house, leveraging its expertise to reliably supply product without relying on third-party manufacturers.
Enrollment is ongoing in ENLIGHTEN I, with enrollment completion anticipated in mid-2023.
Forward Guidance
Lyra Therapeutics anticipates several milestones in 2023, focusing on clinical trial advancements and data reporting.
Positive Outlook
- Resume enrollment in ENLIGHTEN II Phase 3 pivotal trial of LYR-210 in Q2 2023
- Complete enrollment in ENLIGHTEN I Phase 3 pivotal trial of LYR-210 in mid-2023
- Report topline results from BEACON Phase 2 study of LYR-220 in Q4 2023
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...